| 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510] | Technology appraisal guidance | |
| Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
| Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065] | Technology appraisal guidance | TBC |
| Abicipar pegol for treating wet age-related macular degeneration [ID1533] | Technology appraisal guidance | TBC |
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
| Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID6232] | Technology appraisal guidance | |
| Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575] | Technology appraisal guidance | |
| ALXN1840 for treating Wilson disease [ID6422] | Technology appraisal guidance | TBC |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Technology appraisal guidance | |
| Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192] | Technology appraisal guidance | TBC |
| Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732] | Technology appraisal guidance | TBC |
| Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684] | Technology appraisal guidance | |
| Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease
[ID6524] | Technology appraisal guidance | TBC |
| Asunercept for treating glioblastoma [ID1301] | Technology appraisal guidance | TBC |
| Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701] | Technology appraisal guidance | TBC |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
| Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667] | Technology appraisal guidance | TBC |
| Atogepant for treating migraine [ID6615] | Technology appraisal guidance | |
| Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |
| Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707] | Technology appraisal guidance | TBC |
| Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401] | Technology appraisal guidance | TBC |
| Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578] | Technology appraisal guidance | |
| Avelumab for previously treated platinum-resistant ovarian cancer [ID1497] | Technology appraisal guidance | TBC |
| Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261] | Technology appraisal guidance | TBC |
| Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570] | Technology appraisal guidance | TBC |
| Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] | Technology appraisal guidance | TBC |
| Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552] | Technology appraisal guidance | TBC |
| Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541] | Technology appraisal guidance | TBC |
| Baxdrostat for treating uncontrolled or resistant hypertension [ID6623] | Technology appraisal guidance | |
| Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481] | Technology appraisal guidance | TBC |
| Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394] | Technology appraisal guidance | TBC |
| Bepirovirsen for treating chronic hepatitis B [ID6608] | Technology appraisal guidance | TBC |
| Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Technology appraisal guidance | |
| Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537] | Technology appraisal guidance | |
| Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145] | Technology appraisal guidance | |
| Botulinum toxin type A for preventing episodic migraine [ID6450] | Technology appraisal guidance | TBC |
| Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768] | Technology appraisal guidance | TBC |
| Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448] | Technology appraisal guidance | TBC |
| Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437] | Technology appraisal guidance | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325] | Technology appraisal guidance | TBC |
| Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243] | Technology appraisal guidance | |
| Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474] | Technology appraisal guidance | |
| Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653] | Technology appraisal guidance | TBC |
| Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683] | Technology appraisal guidance | |
| Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580] | Technology appraisal guidance | |
| Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639] | Technology appraisal guidance | TBC |
| Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659] | Technology appraisal guidance | |
| Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610] | Technology appraisal guidance | |
| Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612] | Technology appraisal guidance | TBC |
| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012] | Technology appraisal guidance | TBC |
| Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259] | Technology appraisal guidance | TBC |
| Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance | TBC |
| Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
| Daprodustat for treating anaemia in people with chronic kidney disease [ID3987] | Technology appraisal guidance | TBC |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated
multiple myeloma when a stem cell transplant is unsuitable [ID3843] | Technology appraisal guidance | |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249] | Technology appraisal guidance | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297] | Technology appraisal guidance | |
| Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348] | Technology appraisal guidance | TBC |
| DCVax-L for treating glioblastoma [ID836] | Technology appraisal guidance | TBC |
| Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601] | Technology appraisal guidance | |
| Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419] | Technology appraisal guidance | TBC |
| Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400] | Technology appraisal guidance | |
| Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447] | Technology appraisal guidance | TBC |
| Deucravacitinib for treating active psoriatic arthritis [ID6561] | Technology appraisal guidance | TBC |
| Deuruxolitinib for treating severe alopecia areata [ID6597] | Technology appraisal guidance | |
| Deutetrabenazine for treating tardive dyskinesia [ID6550] | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TSID10725] | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726] | Technology appraisal guidance | TBC |
| Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606] | Technology appraisal guidance | TBC |
| Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Technology appraisal guidance | TBC |
| Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457] | Technology appraisal guidance | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326] | Technology appraisal guidance | |
| Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311] | Technology appraisal guidance | TBC |
| Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530] | Technology appraisal guidance | TBC |
| Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314] | Technology appraisal guidance | TBC |
| Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055] | Technology appraisal guidance | TBC |
| Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374] | Technology appraisal guidance | |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317] | Technology appraisal guidance | TBC |
| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097] | Technology appraisal guidance | TBC |
| Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409] | Technology appraisal guidance | |
| Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | TBC |
| Elamipretide for treating Barth syndrome in people of any age [ID6545] | Technology appraisal guidance | TBC |
| Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847] | Technology appraisal guidance | TBC |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586] | Technology appraisal guidance | |
| ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
| Etripamil for treating paroxysmal supraventricular tachycardia [ID6581] | Technology appraisal guidance | TBC |
| Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920] | Technology appraisal guidance | TBC |
| Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032] | Technology appraisal guidance | TBC |
| Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over
[ID6678] | Technology appraisal guidance | TBC |
| Filgotinib for treating axial spondyloarthritis [ID6594] | Technology appraisal guidance | TBC |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514] | Technology appraisal guidance | TBC |
| Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126] | Technology appraisal guidance | TBC |
| Gantenerumab for treating early Alzheimer's disease [ID6142] | Technology appraisal guidance | TBC |
| Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256] | Technology appraisal guidance | TBC |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072] | Technology appraisal guidance | TBC |
| Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323] | Technology appraisal guidance | |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487] | Technology appraisal guidance | TBC |
| Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071] | Technology appraisal guidance | TBC |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] | Technology appraisal guidance | |
| Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] | Technology appraisal guidance | TBC |
| Ianalumab for treating active Sjogren's syndrome ID6634 | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251] | Technology appraisal guidance | TBC |
| Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596] | Technology appraisal guidance | TBC |
| Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579] | Technology appraisal guidance | TBC |
| Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance | TBC |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373] | Technology appraisal guidance | TBC |
| Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279] | Technology appraisal guidance | TBC |
| Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425] | Technology appraisal guidance | TBC |
| Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over
[ID6551] | Technology appraisal guidance | TBC |
| Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992] | Technology appraisal guidance | TBC |
| Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459] | Technology appraisal guidance | |
| Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498] | Technology appraisal guidance | TBC |
| Insulin efsitora alfa for treating type 2 diabetes [ID6499] | Technology appraisal guidance | |
| Insulin icodec for treating type 2 diabetes [ID6175] | Technology appraisal guidance | TBC |
| Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556] | Technology appraisal guidance | |
| Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194] | Technology appraisal guidance | TBC |
| Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738] | Technology appraisal guidance | TBC |
| Iptacopan for treating primary IgA nephropathy
[ID6640] | Technology appraisal guidance | TBC |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067] | Technology appraisal guidance | TBC |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706] | Technology appraisal guidance | TBC |
| Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590] | Technology appraisal guidance | TBC |
| Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687] | Technology appraisal guidance | TBC |
| Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292] | Technology appraisal guidance | |
| Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] | Technology appraisal guidance | TBC |
| Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495] | Technology appraisal guidance | TBC |
| Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410] | Technology appraisal guidance | TBC |
| Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117] | Technology appraisal guidance | TBC |
| Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903] | Technology appraisal guidance | TBC |
| Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390] | Technology appraisal guidance | TBC |
| Lifileucel for previously treated unresectable or metastatic melanoma [ID3863] | Technology appraisal guidance | |
| Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609] | Technology appraisal guidance | TBC |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619] | Technology appraisal guidance | TBC |
| Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517] | Technology appraisal guidance | |
| Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340] | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872] | Technology appraisal guidance | TBC |
| Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526] | Technology appraisal guidance | |
| Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315] | Technology appraisal guidance | TBC |
| Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589] | Technology appraisal guidance | TBC |
| Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941] | Technology appraisal guidance | TBC |
| Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818] | Technology appraisal guidance | TBC |
| Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257] | Technology appraisal guidance | TBC |
| Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy
[ID6523] | Technology appraisal guidance | TBC |
| Melanoma (metastatic) - talimogene laherparepvec [ID508] | Technology appraisal guidance | |
| Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237] | Technology appraisal guidance | |
| Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618] | Technology appraisal guidance | |
| Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527] | Technology appraisal guidance | TBC |
| Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442] | Technology appraisal guidance | TBC |
| Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203] | Technology appraisal guidance | TBC |
| MTX110 for untreated diffuse intrinsic pontine glioma [ID2695] | Technology appraisal guidance | TBC |
| Nemolizumab for treating prurigo nodularis [ID6451] | Technology appraisal guidance | TBC |
| Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446] | Technology appraisal guidance | |
| Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588] | Technology appraisal guidance | TBC |
| Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858] | Technology appraisal guidance | |
| Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316] | Technology appraisal guidance | TBC |
| Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345] | Technology appraisal guidance | TBC |
| Nirogacestat for treating desmoid tumours [ID6453] | Technology appraisal guidance | |
| Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858] | Technology appraisal guidance | |
| Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053] | Technology appraisal guidance | TBC |
| Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690] | Technology appraisal guidance | TBC |
| Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239] | Technology appraisal guidance | |
| Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939] | Technology appraisal guidance | TBC |
| Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475] | Technology appraisal guidance | TBC |
| Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582] | Technology appraisal guidance | |
| Norucholic acid for treating primary sclerosing cholangitis [ID6583] | Technology appraisal guidance | TBC |
| Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195] | Technology appraisal guidance | TBC |
| NY-ESO-1 T-cells for treating synovial sarcoma [ID1286] | Technology appraisal guidance | TBC |
| Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519] | Technology appraisal guidance | |
| Obinutuzumab for treating serologically active extra-renal lupus [ID6670] | Technology appraisal guidance | |
| Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181] | Technology appraisal guidance | TBC |
| Olezarsen for treating familial chylomicronaemia syndrome [ID6585] | Technology appraisal guidance | |
| Omburtamab for treating relapsed neuroblastoma [ID1664] | Technology appraisal guidance | TBC |
| Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941] | Technology appraisal guidance | TBC |
| Orforglipron for managing overweight and obesity [ID6516] | Technology appraisal guidance | |
| Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6223] | Technology appraisal guidance | |
| Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472] | Technology appraisal guidance | TBC |
| Oveporexton for treating type 1 narcolepsy [ID6622] | Technology appraisal guidance | TBC |
| Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144] | Technology appraisal guidance | TBC |
| Palopegteriparatide for treating chronic hypoparathyroidism [ID6380] | Technology appraisal guidance | |
| Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467] | Technology appraisal guidance | TBC |
| Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594] | Technology appraisal guidance | TBC |
| Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489] | Technology appraisal guidance | |
| Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021] | Technology appraisal guidance | TBC |
| Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994] | Technology appraisal guidance | |
| Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363] | Technology appraisal guidance | |
| Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607] | Technology appraisal guidance | |
| Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814] | Technology appraisal guidance | TBC |
| Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724] | Technology appraisal guidance | TBC |
| Pharmalgen for the treatment of bee and wasp venom allergy | Technology appraisal guidance | TBC |
| Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647] | Technology appraisal guidance | TBC |
| Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269] | Technology appraisal guidance | TBC |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975] | Technology appraisal guidance | TBC |
| Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397] | Technology appraisal guidance | |
| Plozasiran for treating familial chylomicronaemia syndrome [ID6593] | Technology appraisal guidance | |
| Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497] | Technology appraisal guidance | TBC |
| Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569] | Technology appraisal guidance | TBC |
| Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540] | Technology appraisal guidance | TBC |
| Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] | Technology appraisal guidance | |
| Remibrutinib for treating chronic spontaneous urticaria
inadequately controlled by H1-antihistamines [ID6356] | Technology appraisal guidance | |
| Renal cell carcinoma Pathways Pilot [ID6186] | Technology appraisal guidance | TBC |
| Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147] | Technology appraisal guidance | TBC |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529] | Technology appraisal guidance | |
| Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478] | Technology appraisal guidance | TBC |
| Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436] | Technology appraisal guidance | TBC |
| Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482] | Technology appraisal guidance | |
| Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307] | Technology appraisal guidance | TBC |
| Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496] | Technology appraisal guidance | TBC |
| Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565] | Technology appraisal guidance | TBC |
| Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] | Technology appraisal guidance | TBC |
| Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092] | Technology appraisal guidance | |
| Ruxolitinib for Prurigo Nodularis [ID6571] | Technology appraisal guidance | TBC |
| Ruxolitinib for treating moderate atopic dermatitis ID6602 | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739] | Technology appraisal guidance | TBC |
| Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454] | Technology appraisal guidance | TBC |
| Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520] | Technology appraisal guidance | TBC |
| Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284] | Technology appraisal guidance | TBC |
| Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563] | Technology appraisal guidance | TBC |
| Seladelpar for previously treated primary biliary cholangitis [ID6429] | Technology appraisal guidance | |
| Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273] | Technology appraisal guidance | TBC |
| Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385] | Technology appraisal guidance | TBC |
| Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458] | Technology appraisal guidance | TBC |
| Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346] | Technology appraisal guidance | TBC |
| Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542] | Technology appraisal guidance | |
| Sipavibart for preventing COVID 19 [ID6282] | Technology appraisal guidance | TBC |
| Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440] | Technology appraisal guidance | TBC |
| Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147] | Technology appraisal guidance | TBC |
| Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654] | Technology appraisal guidance | TBC |
| Sotatercept for treating pulmonary arterial hypertension [ID6163] | Technology appraisal guidance | TBC |
| Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091] | Technology appraisal guidance | TBC |
| Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632] | Technology appraisal guidance | TBC |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Technology appraisal guidance | |
| Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668] | Technology appraisal guidance | |
| Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086] | Technology appraisal guidance | TBC |
| Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer [ID6758] | Technology appraisal guidance | TBC |
| Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Technology appraisal guidance | TBC |
| Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568] | Technology appraisal guidance | |
| Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413] | Technology appraisal guidance | |
| Talacotuzumab for untreated acute myeloid leukaemia [ID1262] | Technology appraisal guidance | TBC |
| Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617] | Technology appraisal guidance | |
| Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401] | Technology appraisal guidance | TBC |
| Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253] | Technology appraisal guidance | TBC |
| Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] | Technology appraisal guidance | TBC |
| Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756] | Technology appraisal guidance | TBC |
| Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379] | Technology appraisal guidance | |
| Third molars (impacted) - prophylactic removal [ID898] | Technology appraisal guidance | TBC |
| Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238] | Technology appraisal guidance | TBC |
| Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267] | Technology appraisal guidance | TBC |
| Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250] | Technology appraisal guidance | TBC |
| Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122] | Technology appraisal guidance | TBC |
| Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113] | Technology appraisal guidance | |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] | Technology appraisal guidance | TBC |
| Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157] | Technology appraisal guidance | TBC |
| Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753] | Technology appraisal guidance | |
| Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351] | Technology appraisal guidance | TBC |
| Tolebrutinib for treating primary progressive multiple sclerosis [ID6574] | Technology appraisal guidance | |
| Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391] | Technology appraisal guidance | TBC |
| Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406] | Technology appraisal guidance | |
| Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557] | Technology appraisal guidance | TBC |
| Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680] | Technology appraisal guidance | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121] | Technology appraisal guidance | TBC |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309] | Technology appraisal guidance | TBC |
| Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651] | Technology appraisal guidance | TBC |
| Upadacitinib for treating giant cell arteritis [ID6299] | Technology appraisal guidance | |
| Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
| Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] | Technology appraisal guidance | TBC |
| Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314] | Technology appraisal guidance | TBC |
| Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879] | Technology appraisal guidance | TBC |
| Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360] | Technology appraisal guidance | TBC |
| Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099] | Technology appraisal guidance | TBC |
| Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425] | Technology appraisal guidance | TBC |
| Vosoritide for treating achondroplasia in people 4 months and over [ID6488] | Technology appraisal guidance | TBC |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance | TBC |
| Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance | TBC |